rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Both Prevents and Reverses Alcohol-Induced Liver Damage and Portal Hypertension

RPEP-006922001Prkacin, I; Separovic, J; Aralicia, G; Perovic, D; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Staresinic, M; Anic, T; Mikus, D; Sikiric, P; Seiwerth, S; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sebecic, B; Boban-Blagaic, A; Kokic, N
Animal StudyPreliminary evidence
The takeaway

BPC-157 both prevented and reversed alcohol-induced portal hypertension and liver lesions in rats, demonstrating remarkable hepatoprotective effects against chronic alcohol damage.

Prevents AND reverses

BPC-157 both prevented liver damage when given with alcohol AND reversed it after damage was established — dual-direction hepatoprotection

What the researchers found

BPC-157 both prevented (when co-administered) and reversed (when given after damage) chronic alcohol-induced portal hypertension and liver lesions in rats, measured by direct portal vein pressure and histological assessment.

Why it matters

Alcoholic liver disease is a leading cause of liver failure and death. A peptide that both prevents AND reverses liver damage could save millions of lives, especially since most liver drugs only slow progression.

How the study worked

Animal study in rats. Chronic alcohol administration (7.28 g/kg/day in drinking water). BPC-157 given preventively (with alcohol) or therapeutically (after liver damage established). Portal vein pressure measured directly. Liver histology assessed.

What this study cannot tell us

Rat alcohol model. The mechanism of hepatoprotection was not determined. Whether BPC-157 can reverse advanced cirrhosis (not just early lesions) is unknown. Human data absent.

How to read the evidence

Preliminary animal evidence with direct hemodynamic measurements (portal pressure) and histological confirmation, demonstrating both prevention and reversal.

When this study was published

Published in 2001. BPC-157's hepatoprotective effects have been further confirmed in subsequent animal studies.

The bigger picture

Most liver disease treatments only slow damage. BPC-157's ability to reverse established portal hypertension and liver lesions suggests it may activate repair mechanisms that existing drugs cannot.

Questions still open

  • Could BPC-157 treat alcoholic liver disease in humans?
  • What mechanism mediates the portal pressure reduction?
  • Does BPC-157 promote liver regeneration or prevent ongoing damage?

Common questions

Can BPC-157 protect the liver from alcohol?
In rats, yes — dramatically. It prevented liver damage when given during alcohol exposure AND reversed existing damage when given after liver injury was established. Both portal hypertension and liver lesions improved.
Could this help alcoholic liver disease patients?
The animal results are remarkably promising. If confirmed in humans, BPC-157 could be valuable for both preventing liver damage in heavy drinkers and treating established alcoholic liver disease. Human trials are needed.

Read the original research

Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.

Journal of physiology, Paris, 95(1-6), 315-24

View on PubMed ↗

Citation

Prkacin, I; Separovic, J; Aralicia, G; Perovic, D; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Staresinic, M; Anic, T; Mikus, D; Sikiric, P; Seiwerth, S; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sebecic, B; Boban-Blagaic, A; Kokic, N. (2001). Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.. Journal of physiology, Paris, 95(1-6), 315-24.